Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065169 · ClinicalTrials.gov registry record · NA
Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 138
- Enrollment target
NCT00065169 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 138 participants.
The verdict
NCT00065169, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 138 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the anti-inflammatory drug celecoxib can delay the onset of Alzheimer Disease (AD) in people with Age Associated Memory Impairment (AAMI). This study will also evaluate genetic risk and brain structure as potential predictors of mental decline.
Interventions
- DRUG Celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2000-11 |
| Est. Completion | 2005-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065169
The ClinicalTrials.gov registry entry for NCT00065169 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Celecoxib is the first listed.
NCT00065169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065169 about?
NCT00065169 is a clinical study titled "Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs". The purpose of this study is to determine whether the anti-inflammatory drug celecoxib can delay the onset of Alzheimer Disease (AD) in people with Age Associated Memory Impairment (AAMI). This study will also evaluate genetic risk and brain structure as potential predictors of mental decline.
What is the current status of trial NCT00065169?
This trial is currently completed. It is a NA study. The enrollment target is 138 participants. The study started on 2000-11. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00065169?
The interventions under investigation include: Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00065169?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.